Tyra Biosciences, Inc. (TYRA) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-02

How it makes money

Clinical trial results drive the ability to sell future medicines.

The company targets patients with specific genetic drivers in cancer and skeletal dysplasia. Revenue depends on whether its lead drug successfully completes its Phase 2 trials.

What growth costs

The company needs substantial additional capital for development.

The company must continuously reinvest in clinical trials and R&D to reach commercialization. It requires significant funding to avoid delays or the termination of its development programs.

What could damage it

Failure to get marketing approval would impair its ability to earn.

The company has no approved products for sale. If its clinical candidates fail to achieve regulatory approval, the company cannot generate revenue from its pipeline.

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Other companies in Biotechnology